Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Weeding Out Pipeline “Dogs” Early Can Be As Valuable As A Blockbuster

Executive Summary

Eliminating "bad" compounds from the pipeline early in the development process can generate as much value as picking a blockbuster, McKinsey Partner Rodney Zemmel suggested Sept. 26

You may also be interested in...

Follow-On Falloff: R&D Slowdown May Reflect Fewer “Me Toos” – Temple

The decline in new molecular entity approvals may reflect decreasing interest by industry in the development of "me too" agents, FDA Office of Medical Policy Director Robert Temple said

Enhanced Phase II Efforts Paying Dividends, But At A Price, Pfizer Exec Says

Expanded approaches to Phase II development have reduced Phase III attrition rates, but in doing so, have also created a new set of challenges for pharmaceutical companies, according to Pfizer Senior VP-Science & Technology Peter Corr

Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers

Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts